Aptar Pharma hosts “The Nasal drug Delivery Journey: From Systemic to Nose-to-Brain" scientific webinar

Webinar will focus on the nasal drug delivery route in the treatment of central nervous system diseases.

The webinar will be presented live and will include interactive exchanges with registered participants.

The Aptar Pharma webinar will feature discussions on the following topics:

• Unmet medical needs and market opportunities for nasal drug delivery to treat CNS diseases

• Drug transport into the CNS via the nasal route

• Nasal drug delivery devices that target CNS-related diseases

• New opportunities in areas such as nose-to-brain drug delivery.

By 2030, one billion people worldwide will be over the age of 65 compared to 600 million today. Healthcare must adjust to these changing demographics. In addition, the world is facing multiple unmet medical needs.

Several changes - new therapeutic options, shorter hospital stays, increased outpatient care and more self-administration of drugs, to name a few – are imperative within a short time frame. The pharmaceutical and biotech industries are striving to provide affordable solutions to these challenges.

This environment provides a wide range of opportunities for the CNS drug market ($145 billion in 2015) in the future treatment of patients. Covering areas such as depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, migraine, insomnia, Attention Deficit Hyperactivity Disorder (ADHD), anxiety and bipolar disorders, new CNS drug delivery options will benefit patients and enhance overall healthcare.